SR 142948A was used to study the role of neurotensin signaling in intracellular alkanization and expression of IL-8 in human pancreatic cancer cells.
SR 142948A is a non-peptide Neurotensin receptor antagonist
SR 142948A is a potent neurotensin receptor antagonist that affects the expression of c-Fos and has properties of antipsychotic agent. It blocks hypothermia and analgesia induced by neurotensin. It blocks the increase in the concentration of Ca+2 induced by the activation of phospholipase C in CHO cell model.
Features and Benefits
This compound is featured on the Neurotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
LOPAC is a registered trademark of Sigma-Aldrich Co. LLC
5, 25 mg in glass bottle